Michael Mueller
Researcher in Psychedelic Research & Therapy Development at the Psychiatric University Clinic Zurich and University of Zurich
Data updated
Research Footprint
Michael Mueller appears in 11 tracked papers (2023–2025), most studied alongside Ayahuasca, DMT and LSD, across Healthy Volunteers, Medicinal Chemistry & Drug Development and Anxiety Disorders.
Most-cited paper: Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants (81 citations).
Frequent co-authors: Milan Scheidegger, Dominik Dornbierer and Anne Aicher.
Background & Research
Michael J. Mueller is a researcher based in Zurich working in psychedelic research and therapy development at the Psychiatric University Clinic Zurich and the University of Zurich. He is the corresponding author on recent studies of innovative DMT/harmine formulations, including pharmacokinetic/pharmacodynamic trials and experiments on creativity, self-other perception, and mindfulness-related outcomes. His publications indicate a translational focus on developing safer, more controllable psychedelic interventions for mental health applications.
Key Impact
He is a leading clinical researcher on ayahuasca-inspired DMT/harmine formulations, contributing to randomized trials and mechanistic studies on their pharmacology, cognition, and psychiatric potential.
Collaboration Network
28 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Michael Mueller is associated with.
Psychiatric University Hospital, Zurich
The Psychiatric University Hospital Zurich (PUK) is affiliated with the University of Zurich and home to Franz Vollenweider's pioneering psychedelic neuroscience group, active since the 1990s; research includes PET imaging with psilocybin, S- and R-ketamine, MDMA, and DMT+harmine formulations, including a completed 2023 RCT of psilocybin (0.215 mg/kg) vs. placebo for major depressive disorder.
View stakeholder →University of Zurich
academicWithin the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.
View stakeholder →Reconnect Labs
Private BiotechReconnect Labs AG is a Swiss clinical-stage company and University of Zurich spin-off developing precision psychopharmacology therapeutics, including sublingual DMT/harmine, sublingual 5-MeO-DMT, and sublingual dexmedetomidine. Founded in 2021 by Dr. Davor Kosanic (CEO) and co-founders from the Psychiatric University Clinic Zurich and ETH Zurich, building on ~30 years of in-human psychedelic research. The company raised CHF 22M+ (CHF 12M equity across Seed 2021 and Series A 2023–2025; CHF 10M in competitive grants from investors including Esperante Ventures, Lionheart Ventures, Negev Capital, and Noetic Fund) before emerging from stealth in August 2025. Their microcarrier-based transmucosal delivery platform (exclusively licensed) dramatically reduces inter-subject PK variability for DMT/harmine vs. oral ayahuasca and eliminates vomiting. RE03 (sublingual dexmedetomidine for insomnia in PTSD) is the most advanced programme with Swissmedic approval and FDA accelerated pathway confirmed.
View stakeholder →University of Basel
academicThe University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
View stakeholder →